Upadacitinib
Abbvie
[' upa ', 'upadacitinib']
prof bg feagan: endoscopic outcomes with upadacitinib in the phase 3 program endoscopic response (ses-cd drop at least 50%) and remission (ses-cd of 4 or less) both greater in both bio-ir and non-bio-ir groups at wk 12 and upa 30 greater than pbo in bio-ir at wk 52 #ddw2023 
I'm a Mayo specialist in evaluation and management of patients with ulcerative colitis and Crohn's disease. Tweets are mine. Retweet doesn't mean endorsement.